Polfa Tarchomin S.A. uses micronisation processes for some of APIs manufactured. Such process basing simple on particle size reduction does not affect quality of API but improves its bioavailability considerably. Micronisation can be useful especially for poorly soluble APIs. The bioavailability can benefit from reinforcing surface of crystals and speed up required dissolution. Decision whether apply micronisation or not is taken when improve formulation in respect to homogeneity is required. This can be achieved by appropriate and reputable particle size of APIs. Polfa Tarchomin S.A. use micronisation for APIs for its solid finished dosage forms and aerosols. Reduced particle size of ingredients can also be advantageous in injectables as well as in semisolid formulations.